family with sequence similarity 13 member AGenealiases: ARHGAP48 · FAM13A1
Q-omics provides the consensus-scored FAM13A profile across patient tissues and cancer cell-line models. FAM13A expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, FAM13A is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, FAM13A RNA expression shows 21,039 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight CESC, KIRC, and ACC as cancer lineages where FAM13A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM13A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM13A survival associations across molecular data types. FAM13A RNA expression shows survival associations in the most cancer types (19), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM13A RNA expression–survival associations across cancer types. High FAM13A expression shows unfavorable associations in CESC, ESCA and UVM, but favorable associations in KIRC, BLCA and CHOL. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for FAM13A RNA expression.
This table summarizes FAM13A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for FAM13A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM13A shows lower tumor expression in THCA, LIHC, COAD, BRCA and LUSC and higher tumor expression in KIRC. The KIRC box plot shows higher FAM13A RNA expression in tumor versus normal tissue (log2 FC = +1.053, t-test p < 0.001).
This table shows molecular features associated with FAM13A in patient tissues and cancer cell lines. In patient samples, FAM13A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM13A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and UPPER_AERODIGESTIVE_TRACT.
